Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 806.57% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 806.57% | -- | -- | -- | -- |
| Cost of Revenue | 4,954.55% | -- | -- | -- | -- |
| Gross Profit | 444.44% | -- | -- | -- | -- |
| SG&A Expenses | 52.41% | 45.56% | 43.08% | 26.85% | 19.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.76% | 62.81% | 60.62% | 49.65% | 29.08% |
| Operating Income | -50.98% | -61.95% | -60.10% | -49.30% | -28.95% |
| Income Before Tax | -54.38% | -66.22% | -66.99% | -55.01% | -34.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.38% | -66.22% | -66.99% | -55.01% | -34.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.38% | -66.22% | -66.99% | -55.01% | -34.53% |
| EBIT | -50.98% | -61.95% | -60.10% | -49.30% | -28.95% |
| EBITDA | -51.11% | -62.10% | -60.25% | -49.41% | -28.97% |
| EPS Basic | -50.24% | -63.27% | -60.92% | -45.19% | -22.24% |
| Normalized Basic EPS | -47.33% | -63.26% | -60.91% | -45.19% | -20.81% |
| EPS Diluted | -50.24% | -63.27% | -60.92% | -45.19% | -22.24% |
| Normalized Diluted EPS | -47.33% | -63.26% | -60.91% | -45.19% | -20.81% |
| Average Basic Shares Outstanding | 2.83% | 1.76% | 3.49% | 6.28% | 9.96% |
| Average Diluted Shares Outstanding | 2.83% | 1.76% | 3.49% | 6.28% | 9.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |